Clinical Trial Update: First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update on first-line jaktinib for acute graft-versus-host disease. The study is in Phase 1/Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Acute Graft Versus Host Disease | Phase 1, Phase 2 | Status: RECRUITING